Counterpoint Mutual Funds LLC Makes New Investment in Zoetis Inc. $ZTS

Counterpoint Mutual Funds LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 42,789 shares of the company’s stock, valued at approximately $5,058,000. Zoetis comprises approximately 0.8% of Counterpoint Mutual Funds LLC’s portfolio, making the stock its 11th largest position.

Other hedge funds have also made changes to their positions in the company. J. Stern & Co. LLP raised its stake in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after acquiring an additional 23,877,416 shares in the last quarter. Norges Bank acquired a new stake in Zoetis in the 4th quarter worth approximately $734,425,000. Vanguard Group Inc. boosted its position in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Nordea Investment Management AB boosted its position in Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the period. Finally, Van ECK Associates Corp grew its holdings in Zoetis by 269.0% during the fourth quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock valued at $300,340,000 after purchasing an additional 1,740,113 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. UBS Group dropped their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Morgan Stanley reissued an “overweight” rating and set a $115.00 target price on shares of Zoetis in a research report on Friday, May 15th. Finally, Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $126.92.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $74.73 on Friday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The business’s 50 day moving average is $84.04 and its two-hundred day moving average is $109.40. The company has a market cap of $31.33 billion, a P/E ratio of 12.39, a P/E/G ratio of 1.17 and a beta of 0.75. Zoetis Inc. has a 12 month low of $71.47 and a 12 month high of $161.77.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Insiders Place Their Bets

In related news, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 11,650 shares of company stock worth $886,384 in the last ninety days. Insiders own 0.22% of the company’s stock.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.